1086 related articles for article (PubMed ID: 30576769)
1. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
2. Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice.
Nuñez-Durán E; Aghajan M; Amrutkar M; Sütt S; Cansby E; Booten SL; Watt A; Ståhlman M; Stefan N; Häring HU; Staiger H; Borén J; Marschall HU; Mahlapuu M
Hepatol Commun; 2018 Jan; 2(1):69-83. PubMed ID: 29404514
[TBL] [Abstract][Full Text] [Related]
3. Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease.
Caputo M; Kurhe Y; Kumari S; Cansby E; Amrutkar M; Scandalis E; Booten SL; Ståhlman M; Borén J; Marschall HU; Aghajan M; Mahlapuu M
FASEB J; 2021 May; 35(5):e21567. PubMed ID: 33891332
[TBL] [Abstract][Full Text] [Related]
4. STK25 is a critical determinant in nonalcoholic steatohepatitis.
Amrutkar M; Chursa U; Kern M; Nuñez-Durán E; Ståhlman M; Sütt S; Borén J; Johansson BR; Marschall HU; Blüher M; Mahlapuu M
FASEB J; 2016 Oct; 30(10):3628-3643. PubMed ID: 27421788
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
[TBL] [Abstract][Full Text] [Related]
6. Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver.
Nerstedt A; Kurhe Y; Cansby E; Caputo M; Gao L; Vorontsov E; Ståhlman M; Nuñez-Durán E; Borén J; Marschall HU; Mashek DG; Saunders DN; Sihlbom C; Hoy AJ; Mahlapuu M
J Lipid Res; 2020 Feb; 61(2):178-191. PubMed ID: 31857389
[TBL] [Abstract][Full Text] [Related]
7. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
[TBL] [Abstract][Full Text] [Related]
8. Genetic Disruption of Protein Kinase STK25 Ameliorates Metabolic Defects in a Diet-Induced Type 2 Diabetes Model.
Amrutkar M; Cansby E; Chursa U; Nuñez-Durán E; Chanclón B; Ståhlman M; Fridén V; Mannerås-Holm L; Wickman A; Smith U; Bäckhed F; Borén J; Howell BW; Mahlapuu M
Diabetes; 2015 Aug; 64(8):2791-804. PubMed ID: 25845663
[TBL] [Abstract][Full Text] [Related]
9. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.
Rajamoorthi A; Arias N; Basta J; Lee RG; Baldán Á
J Lipid Res; 2017 Nov; 58(11):2127-2138. PubMed ID: 28874443
[TBL] [Abstract][Full Text] [Related]
11. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
Kurhe Y; Caputo M; Cansby E; Xia Y; Kumari S; Anand SK; Howell BW; Marschall HU; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2022; 13(2):405-423. PubMed ID: 34624527
[TBL] [Abstract][Full Text] [Related]
12. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
Win S; Min RWM; Zhang J; Kanel G; Wanken B; Chen Y; Li M; Wang Y; Suzuki A; Aung FWM; Murray SF; Aghajan M; Than TA; Kaplowitz N
Hepatology; 2021 Dec; 74(6):3127-3145. PubMed ID: 34331779
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans.
Cansby E; Kulkarni NM; Magnusson E; Kurhe Y; Amrutkar M; Nerstedt A; Ståhlman M; Sihlbom C; Marschall HU; Borén J; Blüher M; Mahlapuu M
FASEB J; 2019 Sep; 33(9):9974-9989. PubMed ID: 31173506
[TBL] [Abstract][Full Text] [Related]
15. Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis.
Kobayashi T; Kanno K; Nguyen PT; Sugiyama A; Kawahara A; Otani Y; Kishikawa N; Ito M; Tazuma S
J Gastroenterol Hepatol; 2020 Dec; 35(12):2140-2150. PubMed ID: 32365405
[TBL] [Abstract][Full Text] [Related]
16. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
18. The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis.
Fondevila MF; Fernandez U; Gonzalez-Rellan MJ; Da Silva Lima N; Buque X; Gonzalez-Rodriguez A; Alonso C; Iruarrizaga-Lejarreta M; Delgado TC; Varela-Rey M; Senra A; Garcia-Outeiral V; Novoa E; Iglesias C; Porteiro B; Beiroa D; Folgueira C; Tojo M; Torres JL; Hernández-Cosido L; Blanco Ó; Arab JP; Barrera F; Guallar D; Fidalgo M; López M; Dieguez C; Marcos M; Martinez-Chantar ML; Arrese M; Garcia-Monzon C; Mato JM; Aspichueta P; Nogueiras R
Hepatology; 2021 Feb; 73(2):606-624. PubMed ID: 32329085
[TBL] [Abstract][Full Text] [Related]
19. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
